Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Targeted cancer therapy selection based on integrative genomic pathway analysis

EF 2013-14

Résumé
How does one personalize cancer treatment? The secret is in the genes. DNA dictates the function and behaviour of every cell in our bodies. By comparing the genes of cancerous cells with those of normal ones, we can discover what makes tumours tick. That is, what drives their biological clocks at an increased rate and makes their cells grow and divide uncontrollably. At the BC Cancer Agency and Michael Smith Genome Sciences Centre, research teams are sequencing the genomes of a growing number of subjects for the Personalized Oncogenomics study, affectionately known as POG. The subjects typically have metastatic cancer, in which tumours have spread extensively. They have often exhausted conventional treatment options. This new experimental approach gives them hope for a cure. The study includes an array of cancer types and calls on the expertise of a multidisciplinary team of doctors and scientists. It joins an international effort to identify targeted therapies, cancer drugs more selective in their ability to kill cancerous cells and spare normal cells. These drugs promise more effective treatment with fewer toxic side effects. Within cells, genes act together in networks and pathways, forming assembly lines for cellular processes. When the DNA sequence is altered by mistake, a delicate genetic balance is swayed, and these networks can be disrupted. A cancer-causing change may, for example, rev up networks involved in cell division and cause tumour formation. A personalized therapy might counteract tumour growth by targeting the disrupted network. In order to identify the network disruption in the first place, the genome (the full genetic code) of an individual’s tumour cells and normal cells must be sequenced. Differences between the tumour sequence and normal sequence can reveal how tumour cells have changed to become cancer-causing. With cutting-edge sequencing technology, a genome can be sequenced in less than a day for under $10,000. The challenge lies in what comes next. How can changes in DNA sequence predict changes in cell function? While many biological networks and pathways are relatively well understood, the vast majority remain unknown. The search for biological meaning in the genome has spawned the development of numerous network and pathway analysis approaches. The power of these methods is that they aim to predict changes in cell function, and can integrate many forms of genomic data to inform that prediction. Among the team working on POG, my role is to investigate network and pathway analysis methods to assess their effectiveness in identifying targeted therapies. Although many such methods exist, there is difficulty in connecting an understanding of networks and pathways to therapeutic options. My goals are to (1) find clues in these networks which suggest the use of specific targeted treatments and (2) use computers to streamline this process so it can be offered to more patients at reduced cost. Every patient is different. Every cancer is personal. Indiscriminate treatments limit our capacity to treat and to cure. They cause painful toxicity and decrease quality of life. In the age of genome technologies, we have the potential to cater treatments to an individual’s and a cancer’s unique genetic fingerprint. Existing network and pathway analysis methods already provide a powerful approach for understanding the inner workings of a cell. Extending their capacity to identify potential personalized therapies may be the next step to better cancer treatment.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311991
Name
Zhao Eric Y
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeted cancer therapy selection based on integrative genomic pathway analysis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer; Drug Sensitivity; Genome Sequencing; Integrative Genomics; Machine Learning; Pathway Analysis; Personalized Medicine
Abstract
How does one personalize cancer treatment? The secret is in the genes. DNA dictates the function and behaviour of every cell in our bodies. By comparing the genes of cancerous cells with those of normal ones, we can discover what makes tumours tick. That is, what drives their biological clocks at an increased rate and makes their cells grow and divide uncontrollably. At the BC Cancer Agency and Michael Smith Genome Sciences Centre, research teams are sequencing the genomes of a growing number of subjects for the Personalized Oncogenomics study, affectionately known as POG. The subjects typically have metastatic cancer, in which tumours have spread extensively. They have often exhausted conventional treatment options. This new experimental approach gives them hope for a cure. The study includes an array of cancer types and calls on the expertise of a multidisciplinary team of doctors and scientists. It joins an international effort to identify targeted therapies, cancer drugs more selective in their ability to kill cancerous cells and spare normal cells. These drugs promise more effective treatment with fewer toxic side effects. Within cells, genes act together in networks and pathways, forming assembly lines for cellular processes. When the DNA sequence is altered by mistake, a delicate genetic balance is swayed, and these networks can be disrupted. A cancer-causing change may, for example, rev up networks involved in cell division and cause tumour formation. A personalized therapy might counteract tumour growth by targeting the disrupted network. In order to identify the network disruption in the first place, the genome (the full genetic code) of an individual’s tumour cells and normal cells must be sequenced. Differences between the tumour sequence and normal sequence can reveal how tumour cells have changed to become cancer-causing. With cutting-edge sequencing technology, a genome can be sequenced in less than a day for under $10,000. The challenge lies in what comes next. How can changes in DNA sequence predict changes in cell function? While many biological networks and pathways are relatively well understood, the vast majority remain unknown. The search for biological meaning in the genome has spawned the development of numerous network and pathway analysis approaches. The power of these methods is that they aim to predict changes in cell function, and can integrate many forms of genomic data to inform that prediction. Among the team working on POG, my role is to investigate network and pathway analysis methods to assess their effectiveness in identifying targeted therapies. Although many such methods exist, there is difficulty in connecting an understanding of networks and pathways to therapeutic options. My goals are to (1) find clues in these networks which suggest the use of specific targeted treatments and (2) use computers to streamline this process so it can be offered to more patients at reduced cost. Every patient is different. Every cancer is personal. Indiscriminate treatments limit our capacity to treat and to cure. They cause painful toxicity and decrease quality of life. In the age of genome technologies, we have the potential to cater treatments to an individual’s and a cancer’s unique genetic fingerprint. Existing network and pathway analysis methods already provide a powerful approach for understanding the inner workings of a cell. Extending their capacity to identify potential personalized therapies may be the next step to better cancer treatment.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhao, Eric Y
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~